- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06063746
Compassionate Use of Vidutolimod
January 6, 2026 updated by: Regeneron Pharmaceuticals
Provide Compassionate Use of Vidutolimob
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
Compassionate use is only available to patients who transitioned from a previous vidutolimod (CMP-001) study.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
September 18, 2023
First Submitted That Met QC Criteria
September 25, 2023
First Posted (Actual)
October 3, 2023
Study Record Updates
Last Update Posted (Actual)
January 8, 2026
Last Update Submitted That Met QC Criteria
January 6, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMP-001-Vidutolimod
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Melanoma
-
National Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditionsUnited States, Canada
-
AstraZenecaCompletedRefractory MelanomaUnited States, Spain, Canada, France, Italy, United Kingdom, Argentina, Australia, Germany
-
Vanderbilt-Ingram Cancer CenterActive, not recruitingMetastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Refractory MelanomaUnited States
-
Providence Health & ServicesBristol-Myers Squibb; ExelixisTerminatedRefractory Cutaneous MelanomaUnited States
-
Krankenhaus NordwestTerminatedChemo-refractory MelanomaGermany
-
National Cancer Institute (NCI)Active, not recruitingStage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
Diakonos Oncology CorporationRecruiting
-
Gregory DanielsImmunotherapy FoundationTerminatedMetastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Melanoma | Refractory Melanoma | Phase 1United States
-
M.D. Anderson Cancer CenterActive, not recruiting
Clinical Trials on Vidutolimod
-
Regeneron PharmaceuticalsTerminatedSquamous Cell Carcinoma of Head and NeckUnited States
-
Regeneron PharmaceuticalsTerminatedNon-Small Cell Lung Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Oropharynx Squamous Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States, Australia
-
Regeneron PharmaceuticalsCompletedMelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbTerminatedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Diwakar DavarCellSight Technologies, Inc.; Checkmate PharmaceuticalsCompletedMelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbTerminatedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States